Cell compositions
AssigneeTakara Shuzo Co., Ltd.
InventorsKiyozo Asada, Haruko Konishi, Nobuto Koyama, Ikunoshin Kato
Life of this patent
Estimating the term…
Abstract
Cell compositions from which cancer cells have been selectively eliminated by using apoptosis inducers specific to cancer cells.
Claims4
A cell composition comprising hematopoietic stem cells from which cancer cells have been substantially eliminated, said composition being obtained by selectively eliminating cancer cells with an apoptosis inducer specific to cancer cells, said cancer cells being not genetically engineered, wherein said apoptosis inducer comprises a compound selected from the group consisting of a fucoidan, a decomposition product of a fucoidan, a dextran sulfate, a decomposition product of a dextran sulfate, a heat treated product of a saccharide compound containing a uronic acid and/or a uronic acid derivative, and 4,5-dihydroxy-2-cyclopenten-1-one represented by the formula:
- 7
A process for obtaining a cell composition comprising hematopoietic stem cells from which cancer cells have been substantially eliminated, said process comprising the steps of:
- (a) obtaining hematopoietic stem cells from the appropriate source;
- (b) adding an apoptosis inducer to said hematopoietic stem cells;
- and
- (c) inducing apoptosis of cancer cells,
- said cancer cells being not genetically engineered, wherein said apoptosis inducer comprises a compound selected from the group consisting of a fucoidan, a decomposition product of a fucoidan, a dextran sulfate, a decomposition product of a dextran sulfate, a heat treated product of a saccharide compound containing a uronic acid and/or a uronic acid derivative, and 4,5-dihydroxy-2-cyclopenten-1-one represented by the formula:
- 8
A cell composition comprising hematopoietic stem cells and as exogenous gene being transferred into said hematopoietic cells, from which cancer cells have been sbstantially eliminated by selectively eliminating cancer cells with an apoptosis inducer specific to cancer cells, said cancer cells being not genetically engineered, wherein said apoptosis inducer comprises a compound selected from the group consisting of a fucoidan, a decomposition product of a fucoidan, a dextran sulfate, a decomposition product of a dextran sulfate, a heat treated product of a saccharide compound containing a uronic acid and/or a uronic acid derivative, and 4, 5-dihydroxy-2-cyclopenten-1-one represented by the formula:
- 9
A process for obtaining a cell composition comprising hematopoietic stem cells and an exogenous gene being transferred into said hematopoietic stem cells, from which cancer cells have been substantially eliminated, said process comprising the steps of:
- (a) obtaining hematopoietic stem cells from the appropriate source;
- (b) adding an apoptosis inducer to said hematopoietic stem cells;
- and
- (c) inducing apoptosis of cancer cells,
- said cancer cells being not genetically engineered, wherein said apoptosis inducer comprises a compound selected from the group consisting of a fucoidan, a decomposition product of a fucoidan, a dextran sulfate, a decomposition product of a dextran sulfate, a heat treated product of a saccharide compound containing a uronic acid and/or a uronic acid derivative, and 4,5-dihydroxy-2-cyclopenten-1-one represented by the formula:
- 10
Dependencies are inferred from the claim text.